Messoud Ashina, MD — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Almotriptan 12.5 Mg Oral TabletIn a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.	Migraine	Phase 4	Traitement symptomatique	Denmark	À vérifier
Ubrogepant 50Mg TabIn a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.	Migraine	Phase 4	Traitement symptomatique	Denmark	À vérifier
Almotriptan 12.5 Mg Oral TabletIn a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.	Migraine	Phase 4	Traitement symptomatique	Denmark	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Almotriptan 12.5 Mg Oral Tablet	Migraine	Phase 4	NCT05214001	ATOM — Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine	TERMINATED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.